Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrin Sangkuhl

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Pharmacogenetics and Genomics|May 7, 2011
PharmGKB summary: citalopram pharmacokinetics pathwayKatrin Sangkuhl, Teri E Klein, Russ B Altman
The Journal of Biological Chemistry|October 3, 2002
Structural requirements for mutational lutropin/choriogonadotropin receptor activationKatrin Sangkuhl, Angela Schulz, Günter Schultz, et al.
Pharmacogenetics and Genomics|September 11, 2009
Selective serotonin reuptake inhibitors pathwayKatrin Sangkuhl, Teri E Klein, Russ B Altman
Pharmacogenetics and Genomics|May 5, 2010
Clopidogrel pathwayKatrin Sangkuhl, Teri E Klein, Russ B Altman
Human Mutation|April 21, 2005
Nephrogenic diabetes insipidus caused by mutation of Tyr205: a key residue of V2 vasopressin receptor functionKatrin Sangkuhl, Holger Römpler, Wibke Busch, et al.
Clinical Pharmacology and Therapeutics|April 13, 2019
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?Rachel Huddart, Katrin Sangkuhl, Michelle Whirl-Carrillo, et al.
Pharmacogenetics and Genomics|June 11, 2009
Cytochrome P450 2D6Ryan P Owen, Katrin Sangkuhl, Teri E Klein, et al.
Drug Metabolism Reviews|October 25, 2008
PharmGKB: understanding the effects of individual genetic variantsKatrin Sangkuhl, Dorit S Berlin, Russ B Altman, et al.
Pharmacogenetics and Genomics|August 27, 2010
PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2Dorit S Berlin, Katrin Sangkuhl, Teri E Klein, et al.
Pharmacogenetics and Genomics|October 13, 2010
Platelet aggregation pathwayKatrin Sangkuhl, Alan R Shuldiner, Teri E Klein, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Pharmacogenetics and Genomics|May 7, 2011
PharmGKB summary: citalopram pharmacokinetics pathwayKatrin Sangkuhl, Teri E Klein, Russ B Altman
The Journal of Biological Chemistry|October 3, 2002
Structural requirements for mutational lutropin/choriogonadotropin receptor activationKatrin Sangkuhl, Angela Schulz, Günter Schultz, et al.
Pharmacogenetics and Genomics|September 11, 2009
Selective serotonin reuptake inhibitors pathwayKatrin Sangkuhl, Teri E Klein, Russ B Altman
Pharmacogenetics and Genomics|May 5, 2010
Clopidogrel pathwayKatrin Sangkuhl, Teri E Klein, Russ B Altman
Human Mutation|April 21, 2005
Nephrogenic diabetes insipidus caused by mutation of Tyr205: a key residue of V2 vasopressin receptor functionKatrin Sangkuhl, Holger Römpler, Wibke Busch, et al.
Clinical Pharmacology and Therapeutics|April 13, 2019
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?Rachel Huddart, Katrin Sangkuhl, Michelle Whirl-Carrillo, et al.
Pharmacogenetics and Genomics|June 11, 2009
Cytochrome P450 2D6Ryan P Owen, Katrin Sangkuhl, Teri E Klein, et al.
Drug Metabolism Reviews|October 25, 2008
PharmGKB: understanding the effects of individual genetic variantsKatrin Sangkuhl, Dorit S Berlin, Russ B Altman, et al.
Pharmacogenetics and Genomics|August 27, 2010
PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2Dorit S Berlin, Katrin Sangkuhl, Teri E Klein, et al.
Pharmacogenetics and Genomics|October 13, 2010
Platelet aggregation pathwayKatrin Sangkuhl, Alan R Shuldiner, Teri E Klein, et al.
Pageof 8